#ScienceLink #Madrid2026 #ESMO26 #OptiTROPBreast01 #SacituzumabTirumotecán
En OptiTROP-Breast01 (fase III; n=263), sacituzumab tirumotecán mantuvo el beneficio en SG frente a QT de elección del investigador en cáncer de mama triple negativo localmente recurrente o metastásico, tras ≥2 líneas sistémicas previas (≥1 en enfermedad metastásica).
⏰ Mediana de seguimiento: 29.4 meses.
📊 Mediana de SG: 14.7 vs 9.9 meses.
HR 0.60 (IC 95%: 0.45–0.80; p nominal=0.0004).
📈 SG a 30 meses: 26.8% vs 13.2%.
⚠️ Sin nuevas señales de seguridad durante el seguimiento prolongado.
🔗 Leer/escuchar noticia completa: https://buff.ly/0K4UAO3
10 views · 0 likes · 0 reposts · 0 replies
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgTroFuse-021/ENGOT-ov85/GOG-3102: Phase 3 study of maintenance sacituzumab tirumotecan (Sac-TMT) with or without bevacizumab versus standard of care in patients with advanced ovarian cancer
https://esmocongress.esmo.orgNeoadjuvant sacituzumab govitecan plus pembrolizumab in resectable non-small cell lung cancer: Phase II CITADEL study
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.orgSource: ScienceLink · x.com